122 related articles for article (PubMed ID: 7913116)
41. Maturation of adult peripheral blood CD38(+)CD4(+) T cells demonstrated by cytokine production in response to a superantigen, TSST-1.
Imanishi K; Kato H; Fujii H; Uchiyama T
Cell Immunol; 2003 Apr; 222(2):89-96. PubMed ID: 12826078
[TBL] [Abstract][Full Text] [Related]
42. [CD38/ADP-ribosyl cyclase, a marker of endothelial dysfunction in bronchial asthma].
Sobko EA; Kraposhina AIu; Demko IV; Salmina AB
Klin Med (Mosk); 2013; 91(2):34-8. PubMed ID: 23718062
[TBL] [Abstract][Full Text] [Related]
43. NKRP1A molecule is involved in transendothelial migration of CD4+ human T lymphocytes.
Poggi A; Costa P; Zocchi MR; Moretta L
Immunol Lett; 1997 Jun; 57(1-3):121-3. PubMed ID: 9232437
[TBL] [Abstract][Full Text] [Related]
44. Lymphocyte adhesion to endothelium.
Dianzani U; Malavasi F
Crit Rev Immunol; 1995; 15(2):167-200. PubMed ID: 8573287
[TBL] [Abstract][Full Text] [Related]
45. Role of CD38 in cell-cell interactions under conditions of endothelial dysfunction.
Inzhutova AI; Salmina AB; Petrova MM; Larionov AA
Bull Exp Biol Med; 2008 Jun; 145(6):703-6. PubMed ID: 19110555
[TBL] [Abstract][Full Text] [Related]
46. CD38: an ecto-enzyme with functional diversity in T cells.
Ghosh A; Khanam A; Ray K; Mathur P; Subramanian A; Poonia B; Kottilil S
Front Immunol; 2023; 14():1146791. PubMed ID: 37180151
[TBL] [Abstract][Full Text] [Related]
47. Functional SARS-CoV-2 cross-reactive CD4
Humbert M; Olofsson A; Wullimann D; Niessl J; Hodcroft EB; Cai C; Gao Y; Sohlberg E; Dyrdak R; Mikaeloff F; Neogi U; Albert J; Malmberg KJ; Lund-Johansen F; Aleman S; Björkhem-Bergman L; Jenmalm MC; Ljunggren HG; Buggert M; Karlsson AC
Proc Natl Acad Sci U S A; 2023 Mar; 120(12):e2220320120. PubMed ID: 36917669
[TBL] [Abstract][Full Text] [Related]
48. Innovative Anti-CD38 and Anti-BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance.
De Novellis D; Fontana R; Giudice V; Serio B; Selleri C
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614086
[TBL] [Abstract][Full Text] [Related]
49. Leukocyte Membrane Enzymes Play the Cell Adhesion Game.
López-Cortés GI; Díaz-Alvarez L; Ortega E
Front Immunol; 2021; 12():742292. PubMed ID: 34887854
[TBL] [Abstract][Full Text] [Related]
50. Immunological age prediction in HIV-infected, ART-treated individuals.
de Armas LR; Pallikkuth S; Pan L; Rinaldi S; Pahwa R; Pahwa S
Aging (Albany NY); 2021 Oct; 13(19):22772-22791. PubMed ID: 34635604
[TBL] [Abstract][Full Text] [Related]
51. Correlation of CD38 expression with the progression of hemorrhagic fever with renal syndrome.
Zhao HD; Li YP; Zhao WW; Li P; Liu HL
Arch Virol; 2021 Sep; 166(9):2399-2406. PubMed ID: 34114140
[TBL] [Abstract][Full Text] [Related]
52. Mass Cytometry Identifies Expansion of T-bet
Couloume L; Ferrant J; Le Gallou S; Mandon M; Jean R; Bescher N; Zephir H; Edan G; Thouvenot E; Ruet A; Debouverie M; Tarte K; Amé P; Roussel M; Michel L
Front Immunol; 2021; 12():653577. PubMed ID: 34017332
[TBL] [Abstract][Full Text] [Related]
53. The role of CD38 in HIV infection.
Lu L; Wang J; Yang Q; Xie X; Huang Y
AIDS Res Ther; 2021 Apr; 18(1):11. PubMed ID: 33820568
[TBL] [Abstract][Full Text] [Related]
54. CD38 in the age of COVID-19: a medical perspective.
Horenstein AL; Faini AC; Malavasi F
Physiol Rev; 2021 Oct; 101(4):1457-1486. PubMed ID: 33787351
[TBL] [Abstract][Full Text] [Related]
55. IFN-γ and CD38 in Hyperprogressive Cancer Development.
Angelicola S; Ruzzi F; Landuzzi L; Scalambra L; Gelsomino F; Ardizzoni A; Nanni P; Lollini PL; Palladini A
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33467713
[TBL] [Abstract][Full Text] [Related]
56. Immunological imprint of COVID-19 on human peripheral blood leukocyte populations.
Kratzer B; Trapin D; Ettel P; Körmöczi U; Rottal A; Tuppy F; Feichter M; Gattinger P; Borochova K; Dorofeeva Y; Tulaeva I; Weber M; Grabmeier-Pfistershammer K; Tauber PA; Gerdov M; Mühl B; Perkmann T; Fae I; Wenda S; Führer H; Henning R; Valenta R; Pickl WF
Allergy; 2021 Mar; 76(3):751-765. PubMed ID: 33128792
[TBL] [Abstract][Full Text] [Related]
57. Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions.
Caraccio C; Krishna S; Phillips DJ; Schürch CM
Front Immunol; 2020; 11():501. PubMed ID: 32391000
[TBL] [Abstract][Full Text] [Related]
58. Roles of CD38 in the Immune Response to Infection.
Glaría E; Valledor AF
Cells; 2020 Jan; 9(1):. PubMed ID: 31963337
[TBL] [Abstract][Full Text] [Related]
59. Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma.
Huang H; Wu HW; Hu YX
J Zhejiang Univ Sci B; 2020 Jan.; 21(1):29-41. PubMed ID: 31898440
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
